Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 127 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Heart Transplant Surgery Clear all

Conditions: Right Ventricular Dysfunction, Stroke Volume Index, Longitudinal Heart Strain
Interventions: Not listed
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Postoperative Kidney Injury
Interventions: human albumin 5%, HES 130/0.4 (Voluven); Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 40 Years to 85 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Coronary Disease, Heart Diseases, Cardiovascular Diseases, Neurologic Manifestations
Interventions: Magnesium, 0.9% saline; Drug
Lead sponsor: Duke University; Other
Eligibility: 55 Years and older
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Coronary Artery Disease (CAD), Coronary Artery Bypass Graft Surgery(CABG)
Interventions: EA-230 90mg/kg/hour, Placebo; Drug
Lead sponsor: EBI Anti Sepsis BV; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Rochester, Minnesota • Pittsburgh, Pennsylvania

Conditions: Cardiovascular Disease
Interventions: Integrative Therapies Intervention; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Sudden Cardiac Death, Ventricular Fibrillation, Ventricular Tachycardia, Ventricular Dysfunction, Myocardial Ischemia
Interventions: wearable defibrillator (LifeVest); Device
Lead sponsor: Zoll Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 5
States / cities: Sacramento, California • Atlanta, Georgia • Takoma Park, Maryland + 2 more

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Dallas, Texas • Plano, Texas

Conditions: Lung Injury, Pulmonary Complication
Interventions: Fraction of Inspired Oxygen; Other
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Cardio-pulmonary Bypass, Coronary Artery Bypass Graft
Interventions: pexelizumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 168
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 120 more

Conditions: Blood Loss, Surgical
Interventions: Ecallantide, Placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 85 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 8 more

Conditions: Coronary Artery Disease
Interventions: CorMatrix extra cellular matrix (ECM); Device
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Congestive Heart Failure
Interventions: BMAC, CABG only; Biological · Procedure
Lead sponsor: Harvest Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Houston, Texas • Salt Lake City, Utah

Conditions: Coronary Artery Bypass Grafting, Heart Diseases, Heart Valve Diseases
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Kidney Injury
Interventions: Digoxin Antibodies Fab Fragments, Placebo, Baseline EO > 360 pM, EO < 360 pM; Drug · Other · Diagnostic Test
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Non ST Elevation Myocardial Infarction
Interventions: Eptifibatide, Placebo; Drug
Lead sponsor: Medical University of Silesia; Other
Eligibility: 21 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Coronary Artery Bypass Grafting, Mitral Valve Surgery, Low Cardiac Output Syndrome
Interventions: Levosimendan, Placebo; Drug
Lead sponsor: Tenax Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 882 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 49
States / cities: Burlington, Alabama • Huntsville, Alabama • Sacramento, California + 41 more

Conditions: Atrial Fibrillation, Atrial Flutter
Interventions: RSD1235; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Fort Lauderdale, Florida • Atlanta, Georgia

Conditions: Coronary Artery Disease (CAD)
Interventions: XC001, A195/placebo; Drug
Lead sponsor: XyloCor Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Coronary Artery Disease
Interventions: MICS CABG, Conventional CABG; Procedure
Lead sponsor: Ottawa Heart Institute Research Corporation; Other
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • La Crosse, Wisconsin

Conditions: AKI
Interventions: Low Dose RBT-1, High Dose RBT-1, Placebo; Drug
Lead sponsor: Renibus Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 18
States / cities: Huntsville, Alabama • Los Angeles, California • Santa Barbara, California + 15 more

Conditions: Hyperglycemia
Interventions: Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Postoperative Hemorrhage
Interventions: Aprotinin (Trasylol, BAYA0128); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 17
States / cities: Decatur, Alabama • Glendale, California • Pismo Beach, California + 13 more

Conditions: Mitral Valve Insufficiency, Coronary Artery Disease
Interventions: Mitral Valve Repair, CABG; Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 19
States / cities: Los Angeles, California • Atlanta, Georgia • Marietta, Georgia + 16 more

Conditions: Heart Diseases, Coronary Artery Disease, Chest Pain, Stenosis Coronary, STEMI
Interventions: TEE probe; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 100 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Relationship Between Strain and Stroke Volume in Cardiac Surgery

Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical Patients

Effects of Magnesium on Individuals Undergoing Coronary Artery Bypass Graft Surgery

A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.

Usefulness of Integrative Medicine Tools As Adjunctive Care for Women After Coronary Artery Bypass Grafting

LifeVest Post-CABG Registry

Study to Improve Long Term Vein Graft Patency After Coronary Bypass Surgery by Using a Novel Endoscopic Harvesting Technique

Intra-operative Fraction of Inspired Oxygen and Lung Injury in Coronary Artery Bypass Grafting Surgery

Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass

Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement

CorMatrix ECM Study: To Identify Inflammatory Markers Following CABG With/Without ECM

Feasibility Study of BMAC Enhanced CABG

The Short Form-36: Pre- Versus Post-Surgical Administration in Cardiac Surgery Patients

Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI

Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up

Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass

Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery

Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG

The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial

Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

Aprotinin US Special Access Protocol

Comparing the Effectiveness of a Mitral Valve Repair Procedure in Combination With Coronary Artery Bypass Grafting (CABG) Versus CABG Alone in People With Moderate Ischemic Mitral Regurgitation

Intraoperative Echocardiography in Low-Risk CABG Surgery